首页 > 最新文献

Cardiology Research最新文献

英文 中文
Ultrasound-Accelerated Catheter-Directed Thrombolysis. 超声加速导管导向溶栓。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-06-01 DOI: 10.14740/cr1490
Mrhaf Alsamman, Ali Mohsin Choudhry, Abdulaziz Mheir AlSaadi, Rakesh Prashad

Venous thromboembolism is a very common presentation in the hospital setting. In patients with high-risk pulmonary embolism (PE) or PE and hemodynamic instability, systemic thrombolytic treatment is generally indicated. In those with contraindications to systemic thrombolysis, catheter-directed local thrombolytic therapy and surgical embolectomy are currently considered. In particular, catheter-directed thrombolysis (CDT) is a drug delivery system coupling the endovascular drug administration nearby in the thrombus and the local facilitating effect of ultrasounds. The applications of CDT are currently debated. Here we provide a systematic review of the clinical utilization of CDT.

静脉血栓栓塞是一种非常常见的表现在医院设置。对于高危肺栓塞(PE)或PE伴血流动力学不稳定的患者,通常需要进行全身溶栓治疗。对于那些有全身性溶栓禁忌症的患者,目前考虑采用导管定向的局部溶栓治疗和手术栓塞切除术。特别是导管溶栓(CDT)是一种结合血栓附近血管内给药和超声局部促进作用的给药系统。CDT的应用目前存在争议。在此,我们对CDT的临床应用进行了系统的综述。
{"title":"Ultrasound-Accelerated Catheter-Directed Thrombolysis.","authors":"Mrhaf Alsamman,&nbsp;Ali Mohsin Choudhry,&nbsp;Abdulaziz Mheir AlSaadi,&nbsp;Rakesh Prashad","doi":"10.14740/cr1490","DOIUrl":"https://doi.org/10.14740/cr1490","url":null,"abstract":"<p><p>Venous thromboembolism is a very common presentation in the hospital setting. In patients with high-risk pulmonary embolism (PE) or PE and hemodynamic instability, systemic thrombolytic treatment is generally indicated. In those with contraindications to systemic thrombolysis, catheter-directed local thrombolytic therapy and surgical embolectomy are currently considered. In particular, catheter-directed thrombolysis (CDT) is a drug delivery system coupling the endovascular drug administration nearby in the thrombus and the local facilitating effect of ultrasounds. The applications of CDT are currently debated. Here we provide a systematic review of the clinical utilization of CDT.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"14 3","pages":"161-166"},"PeriodicalIF":1.9,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/7c/cr-14-161.PMC10257504.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9621243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chest Pain in Acute Myocardial Infarction and Its Association With the Culprit Artery and Fibrotic Segment Identified by Cardiac Magnetic Resonance. 急性心肌梗死胸痛及其与心脏磁共振鉴定的罪魁动脉和纤维化段的关系。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-04-01 DOI: 10.14740/cr1468
Weverton Ferreira Leite, Rui Manuel Dos Santos Povoa, Adriano Mendes Caixeta, Celso Amodeo, Gilberto Szarf, Maria Teresa Nogueira Bombig, Maria Cristina Oliveira Izar, Luciana Netto Gioia, Wilma Noia Ribeiro, Francisco Antonio Helfenstein Fonseca

Background: It is still very controversial whether the characteristics of pain in the acute myocardial infarction could be related to the culprit coronary artery. There are no data about associations of pain with the ST-segment elevation myocardial infarction (STEMI) and left ventricular (LV) fibrotic segments.

Methods: Data from 328 participants who had STEMI and were included in the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study were analyzed. The culprit artery was identified by coronary angiography and the injured myocardial segments by cardiac magnetic resonance. The statistical significance was established by P value < 0.05.

Results: A total of 223 patients (68%) were selected. Association was not observed between chest pain and the culprit artery (P = 0.237), as well as between pain irradiation and the culprit artery (P = 0.473). No significant difference was observed in the pain localization in relation to the segments in the short axis basal, mid, apical, and long axis, except for the mid inferior segment. The data were not considered clinically relevant because this association was observed in only one of 17 segments after multiple comparisons.

Conclusions: In patients with STEMI, no associations were observed between the location or irradiation of acute chest pain and/or adjacent areas and the culprit artery, or between pain and segmental myocardial fibrosis in the LV.

背景:急性心肌梗死的疼痛特征是否与罪魁祸首冠状动脉有关,目前还存在很大争议。没有关于疼痛与st段抬高型心肌梗死(STEMI)和左心室(LV)纤维化段相关的数据。方法:对328名STEMI患者的数据进行分析,这些患者被纳入急性心肌梗死B型和T型淋巴细胞评估(BATTLE-AMI)研究。通过冠状动脉造影和心脏磁共振检查确定了损伤的心肌节段。P值< 0.05为差异有统计学意义。结果:共入选223例(68%)。胸痛与罪魁动脉无相关性(P = 0.237),疼痛照射与罪魁动脉无相关性(P = 0.473)。除中下节段外,短轴、基轴、中轴、尖轴和长轴节段的疼痛定位无显著差异。这些数据不被认为具有临床相关性,因为在多次比较后,在17个节段中仅观察到这种关联。结论:在STEMI患者中,急性胸痛和/或邻近区域的位置或照射与罪魁动脉之间,或左室疼痛与节段性心肌纤维化之间没有关联。
{"title":"Chest Pain in Acute Myocardial Infarction and Its Association With the Culprit Artery and Fibrotic Segment Identified by Cardiac Magnetic Resonance.","authors":"Weverton Ferreira Leite,&nbsp;Rui Manuel Dos Santos Povoa,&nbsp;Adriano Mendes Caixeta,&nbsp;Celso Amodeo,&nbsp;Gilberto Szarf,&nbsp;Maria Teresa Nogueira Bombig,&nbsp;Maria Cristina Oliveira Izar,&nbsp;Luciana Netto Gioia,&nbsp;Wilma Noia Ribeiro,&nbsp;Francisco Antonio Helfenstein Fonseca","doi":"10.14740/cr1468","DOIUrl":"https://doi.org/10.14740/cr1468","url":null,"abstract":"<p><strong>Background: </strong>It is still very controversial whether the characteristics of pain in the acute myocardial infarction could be related to the culprit coronary artery. There are no data about associations of pain with the ST-segment elevation myocardial infarction (STEMI) and left ventricular (LV) fibrotic segments.</p><p><strong>Methods: </strong>Data from 328 participants who had STEMI and were included in the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study were analyzed. The culprit artery was identified by coronary angiography and the injured myocardial segments by cardiac magnetic resonance. The statistical significance was established by P value < 0.05.</p><p><strong>Results: </strong>A total of 223 patients (68%) were selected. Association was not observed between chest pain and the culprit artery (P = 0.237), as well as between pain irradiation and the culprit artery (P = 0.473). No significant difference was observed in the pain localization in relation to the segments in the short axis basal, mid, apical, and long axis, except for the mid inferior segment. The data were not considered clinically relevant because this association was observed in only one of 17 segments after multiple comparisons.</p><p><strong>Conclusions: </strong>In patients with STEMI, no associations were observed between the location or irradiation of acute chest pain and/or adjacent areas and the culprit artery, or between pain and segmental myocardial fibrosis in the LV.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"14 2","pages":"97-105"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/e0/cr-14-097.PMC10116939.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9742655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad. 尿酸转运蛋白1与其他尿酸转运蛋白的微妙串扰在多替努拉德诱导的慢性肾病和心血管疾病中可能存在。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-04-01 DOI: 10.14740/cr1496
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Hisayuki Katsuyama
We previously reported that the switching from fenofibrate to the selective peroxisome proliferator-activated receptor (PPAR) α modulator, pemafibrate, increased serum uric acid (UA) levels and reduced estimated glomerular filtration rate (eGFR) in patients with dyslipidemia [1]. Fenofibrate has a property to decrease serum UA by inhibition of urate transporter 1 (URAT1) by its major metabolite [2]. Although fenofibrate was reported to decrease the eGFR [3], the mechanism of fenofibrate-induced renal impairment has been remained unclear. Further, our previous discussion on such issue was premature [1]. Recently, the role of UA transporters has been clarified [4] (Fig. 1a). Renal excretion of UA is the major regulator of serum UA, and renal UA reabsorption is mainly mediated by URAT1 and glucose transporter 9 (GLUT9). Organic anion transporters (OATs) 1, 3 transport UA from the renal interstitial into renal proximal tubule epithelial cells. ATP-binding cassette, subfamily G, 2 (ABCG2) has been identified as a high-capacity UA exporter that mediates renal and/or extrarenal UA excretion. Indoxyl sulfate (IS) is a well-known uremic toxin that accumulates under renal impairment and is involved in the progression of chronic kidney disease (CKD) and cardiovascular disease (CVD), by inducing inflammation and free radical production [5, 6]. IS excretion is also mediated by OAT1/3 and ABCG2 as well as UA excretion [4]. ABCG2 inhibitors, such as febuxostat (xanthin oxidase (XO) inhibitor), caused renal IS accumulation by suppressing its excretion via ABCG2 in rats [7]. Fenofibrate completely inhibits ABCG2 which may lead to increase in renal IS [8], resulting in elevation of eGFR. Another XO inhibitor, topiroxostat, also inhibits ABCG2, however, allopurinol does not inhibit ABCG2. OAT inhibitors such as probenecid (uricosuric drug, URAT1, and GLUT9 inhibitor), suppressed IS uptake into the kidney, leading to increased plasma IS [7]. Increased plasma IS may be harmful to cardiovascular system by inducing inflammation and free radical production. Benzbromarone (uricosuric drug) inhibits OAT1 and OAT3, however, its inhibitory potency for OAT1/3 is lower than those of probenecid [9], which may not lead to an increase in plasma IS. Probenecid and benzbromarone inhibit ABCG2, which may be unfavorably associated with renal function. In short, the inhibition of OAT1/3 and ABCG2 increase IS in plasma and kidney, which may be unfavorably associated with the development of CVD and CKD, respectively. Very recently, we reported that the addition of the selective URAT1 inhibitor dotinurad to highly-evidence-proved drugs to improve CKD such as sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist, improved eGFR in a diabetic patient with CKD stage G4 [10]. Dotinurad inhibits URAT1 specifically, however, does not inhibit ABCG2 [9], and reduces renal UA accumulation, which may increase the transport of renal accumulated IS b
{"title":"A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad.","authors":"Hidekatsu Yanai,&nbsp;Hiroki Adachi,&nbsp;Mariko Hakoshima,&nbsp;Hisayuki Katsuyama","doi":"10.14740/cr1496","DOIUrl":"https://doi.org/10.14740/cr1496","url":null,"abstract":"We previously reported that the switching from fenofibrate to the selective peroxisome proliferator-activated receptor (PPAR) α modulator, pemafibrate, increased serum uric acid (UA) levels and reduced estimated glomerular filtration rate (eGFR) in patients with dyslipidemia [1]. Fenofibrate has a property to decrease serum UA by inhibition of urate transporter 1 (URAT1) by its major metabolite [2]. Although fenofibrate was reported to decrease the eGFR [3], the mechanism of fenofibrate-induced renal impairment has been remained unclear. Further, our previous discussion on such issue was premature [1]. Recently, the role of UA transporters has been clarified [4] (Fig. 1a). Renal excretion of UA is the major regulator of serum UA, and renal UA reabsorption is mainly mediated by URAT1 and glucose transporter 9 (GLUT9). Organic anion transporters (OATs) 1, 3 transport UA from the renal interstitial into renal proximal tubule epithelial cells. ATP-binding cassette, subfamily G, 2 (ABCG2) has been identified as a high-capacity UA exporter that mediates renal and/or extrarenal UA excretion. Indoxyl sulfate (IS) is a well-known uremic toxin that accumulates under renal impairment and is involved in the progression of chronic kidney disease (CKD) and cardiovascular disease (CVD), by inducing inflammation and free radical production [5, 6]. IS excretion is also mediated by OAT1/3 and ABCG2 as well as UA excretion [4]. ABCG2 inhibitors, such as febuxostat (xanthin oxidase (XO) inhibitor), caused renal IS accumulation by suppressing its excretion via ABCG2 in rats [7]. Fenofibrate completely inhibits ABCG2 which may lead to increase in renal IS [8], resulting in elevation of eGFR. Another XO inhibitor, topiroxostat, also inhibits ABCG2, however, allopurinol does not inhibit ABCG2. OAT inhibitors such as probenecid (uricosuric drug, URAT1, and GLUT9 inhibitor), suppressed IS uptake into the kidney, leading to increased plasma IS [7]. Increased plasma IS may be harmful to cardiovascular system by inducing inflammation and free radical production. Benzbromarone (uricosuric drug) inhibits OAT1 and OAT3, however, its inhibitory potency for OAT1/3 is lower than those of probenecid [9], which may not lead to an increase in plasma IS. Probenecid and benzbromarone inhibit ABCG2, which may be unfavorably associated with renal function. In short, the inhibition of OAT1/3 and ABCG2 increase IS in plasma and kidney, which may be unfavorably associated with the development of CVD and CKD, respectively. Very recently, we reported that the addition of the selective URAT1 inhibitor dotinurad to highly-evidence-proved drugs to improve CKD such as sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon-like peptide 1 (GLP-1) receptor agonist, improved eGFR in a diabetic patient with CKD stage G4 [10]. Dotinurad inhibits URAT1 specifically, however, does not inhibit ABCG2 [9], and reduces renal UA accumulation, which may increase the transport of renal accumulated IS b","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"14 2","pages":"158-160"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/15/cr-14-158.PMC10116931.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9742656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium Chloride Physiological Saline Solution Versus Water Preparations Injectable in the Use of Shockwave Intravascular Lithotripsy: A Single-Center Experience. 在冲击波血管内碎石术中使用氯化钠生理盐水溶液与注射水制剂:单中心经验。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-04-01 DOI: 10.14740/cr1489
Quentin Landolff, Matthieu Godin, Alexandre Canville, Benjamin Honton, Jacques Monsegu, Marine Quillot, Jacques Berland, Rene Koning, Nicolas Amabile

Background: Shockwave intravascular lithotripsy (IVL) coronary system is a very useful new technology for de novo severely calcified coronary artery plaques before percutaneous coronary intervention (PCI). The device uses a semi-compliant low-pressure balloon, integrated into a sterile catheter, to deliver by vaporizing fluid an expanding bubble that generates high-pressure ultrasonic energy by waves that create multiplane longitudinal micro-macro fractures in calcified plaques, which facilitate optimal stent placement and expansion, and luminal gain.

Methods: The use of Shockwave IVL coronary system in our cardiac catheterization laboratory (Cath lab) at the "Clinique Saint-Hilaire" in Rouen, France, started in March 2019, with 42 procedures performed since this date: two patients in 2019, two patients in 2020, seven patients in 2021, 23 patients in 2022, and eight patients since the beginning of 2023.

Results: We had experienced problems at the beginning of our activity for the first 11 patients (two patients in 2019, two patients in 2020, and seven patients in 2021): after less than five pulses, the shock therapy stopped. We used initially for Shockwave IVL semi-compliant low-pressure integrated balloons a mixture of 50% contrast and 50% water preparations injectable (PPI). After changing water PPI by sodium chloride physiological saline solution, we never encountered this problem again for the following 31 patients (23 patients in 2022, and eight patients since the beginning of 2023). In fact, the proper functioning of Shockwave IVL system requires ions in balloon mixture in addition to the contrast. It is thanks to the ions contained in sodium chloride physiological saline solution that the spark necessary for shocks delivery after balloon inflation is produced.

Conclusions: Water PPI or sodium chloride physiological saline solution is used in angioplasty balloons in a lot of Cath labs worldwide. It is therefore essential to disseminate in the worldwide Cath lab the obligation to put in Shockwave IVL semi-compliant low-pressure integrated balloons sodium chloride physiological saline solution, rather than water PPI for optimal performance, and the importance of Shockwave Medical reporting this to interventional cardiologists.

背景:冲击波血管内碎石(IVL)冠状动脉系统是一种非常有用的新技术,用于经皮冠状动脉介入治疗(PCI)前新发严重钙化的冠状动脉斑块。该设备使用半兼容的低压球囊,整合到无菌导管中,通过汽化液体产生一个膨胀的气泡,通过波浪产生高压超声能量,在钙化斑块中产生多平面纵向微宏观断裂,从而促进最佳支架放置和扩张,并获得管腔增益。方法:我们在法国鲁昂“圣伊莱尔诊所”的心导管实验室(Cath lab)于2019年3月开始使用冲击波IVL冠状动脉系统,自该日起共进行了42例手术:2019年2例,2020年2例,2021年7例,2022年23例,2023年初至今8例。结果:前11例患者(2019年2例,2020年2例,2021年7例)在活动开始时就遇到了问题:在不到5次脉冲后,休克治疗停止。我们最初使用的冲击波IVL半顺从低压一体化气球是50%造影剂和50%可注射水制剂(PPI)的混合物。在用氯化钠生理盐水溶液改变水PPI后,以下31例患者(2022年23例,2023年初至今8例)没有再出现此问题。事实上,冲击波IVL系统的正常工作除了需要造影剂外,还需要球囊混合物中的离子。正是由于氯化钠生理盐水中所含的离子,才产生了气球充气后冲击传递所需的火花。结论:国内外许多导管实验室均采用水PPI或氯化钠生理盐水溶液作为血管成形术球囊。因此,有必要在世界范围内的导管室宣传在冲击波IVL半合规低压集成气囊中放入氯化钠生理盐水溶液,而不是水PPI以获得最佳性能的义务,以及冲击波医学向介入心脏病专家报告这一情况的重要性。
{"title":"Sodium Chloride Physiological Saline Solution Versus Water Preparations Injectable in the Use of Shockwave Intravascular Lithotripsy: A Single-Center Experience.","authors":"Quentin Landolff,&nbsp;Matthieu Godin,&nbsp;Alexandre Canville,&nbsp;Benjamin Honton,&nbsp;Jacques Monsegu,&nbsp;Marine Quillot,&nbsp;Jacques Berland,&nbsp;Rene Koning,&nbsp;Nicolas Amabile","doi":"10.14740/cr1489","DOIUrl":"https://doi.org/10.14740/cr1489","url":null,"abstract":"<p><strong>Background: </strong>Shockwave intravascular lithotripsy (IVL) coronary system is a very useful new technology for <i>de novo</i> severely calcified coronary artery plaques before percutaneous coronary intervention (PCI). The device uses a semi-compliant low-pressure balloon, integrated into a sterile catheter, to deliver by vaporizing fluid an expanding bubble that generates high-pressure ultrasonic energy by waves that create multiplane longitudinal micro-macro fractures in calcified plaques, which facilitate optimal stent placement and expansion, and luminal gain.</p><p><strong>Methods: </strong>The use of Shockwave IVL coronary system in our cardiac catheterization laboratory (Cath lab) at the \"Clinique Saint-Hilaire\" in Rouen, France, started in March 2019, with 42 procedures performed since this date: two patients in 2019, two patients in 2020, seven patients in 2021, 23 patients in 2022, and eight patients since the beginning of 2023.</p><p><strong>Results: </strong>We had experienced problems at the beginning of our activity for the first 11 patients (two patients in 2019, two patients in 2020, and seven patients in 2021): after less than five pulses, the shock therapy stopped. We used initially for Shockwave IVL semi-compliant low-pressure integrated balloons a mixture of 50% contrast and 50% water preparations injectable (PPI). After changing water PPI by sodium chloride physiological saline solution, we never encountered this problem again for the following 31 patients (23 patients in 2022, and eight patients since the beginning of 2023). In fact, the proper functioning of Shockwave IVL system requires ions in balloon mixture in addition to the contrast. It is thanks to the ions contained in sodium chloride physiological saline solution that the spark necessary for shocks delivery after balloon inflation is produced.</p><p><strong>Conclusions: </strong>Water PPI or sodium chloride physiological saline solution is used in angioplasty balloons in a lot of Cath labs worldwide. It is therefore essential to disseminate in the worldwide Cath lab the obligation to put in Shockwave IVL semi-compliant low-pressure integrated balloons sodium chloride physiological saline solution, rather than water PPI for optimal performance, and the importance of Shockwave Medical reporting this to interventional cardiologists.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"14 2","pages":"149-152"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/e3/cr-14-149.PMC10116940.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9445393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Left Atrial Remodeling in Patients With Severe Rheumatic Mitral Stenosis and Sinus Rhythm Using Two-Dimensional and Three-Dimensional Speckle Tracking Echocardiography. 二维和三维斑点跟踪超声心动图在严重风湿性二尖瓣狭窄和窦性心律患者左房重构中的应用。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-04-01 DOI: 10.14740/cr1465
Taher Said Abd Elkareem, Taghreed Abdelrahman Ahmed, Layla Ahmed Mohamed

Background: In mitral stenosis (MS), the combination of an increase in left atrium (LA) pressure and atrial inflammatory response is accompanied by increase in interstitial fibrosis of the atrial wall with disorganization of atrial muscle bundles, LA dysfunction and subsequently LA dilatation. We aimed to assess the effect of severe rheumatic MS on LA volumes and mechanics.

Methods: We enrolled 40 patients with pure severe rheumatic MS and sinus rhythm as a patient group and 30 healthy subjects as a control group. All patient and control groups underwent two-dimensional (2D) transthoracic echo to measure left ventricle (LV) dimensions, function, LA deformations, estimated systolic pulmonary artery pressure (EPAP), and left ventricle global longitudinal strain (LV GLS). Also LA volumes and mechanics (LA strain during LV systole (reservoir function) and LV diastole (early = conduit, and late = booster pump = atrial contraction)) were measured by three-dimensional (3D) transthoracic echo; mitral valve (MV) area was measured by 3D transesophageal echo (as routine pre-percutaneous MV commissurotomy using multiplanar reconstruction in mid-esophageal apical long-axis view from LA prospective).

Results: By 2D transthoracic echo, patient group revealed significantly lower all LA function vs. control group including LA strain during reservoir (24 ± 6 vs. 43 ± 3, P < 0.001), LA strain during conduit (-11 ± 3 vs. -25 ± 2, P < 0.001), and during booster pump (-13 ± 4 vs. -18 ± 1, P < 0.001). EPAP was significantly higher in patient group (48 ± 7 vs. 27 ± 4 in control group). LV GLS was significantly lower in patient group (-16±2% vs. -23±2% in control group). All 3D LA volumes were significantly higher in patient group than control group including maximum LA volume (LAVmax) (76 ± 18 vs. 50 ± 5, P < 0.001), indexed LA volume (LAVi) (44.6 ± 10.1 vs. 28.7 ± 3.7, P < 0.001), LV minimum volume (LAVmin) (51 ± 15 vs. 30 ± 4, P < 0.001), and LA volume pre atrial contraction (LAVpre A) (63 ± 15 vs. 41 ± 6, P < 0.001). Also, there was significantly decreased LA strain using 3D speckle tracking echo in patient group including systolic deformation of LA (reservoir function) (23 ± 6 vs. 41 ± 3, P < 0.001) and diastolic deformation, early diastole (conduit function) (-10 ± 2 vs. -24 ± 2, P < 0.001), and late diastole (booster pump function) (-13 ± 4 vs. -18 ± 1, P < 0.001).

Conclusions: All LA function markedly reduced in pure severe rheumatic MS. The reduction of LA mechanics is directly related to the degree of reduction of the stenotic MV area. LV GLS significantly reduced in severe MS and its reduction is directly related to the degree of reduction of the stenotic MV area and the LAVi by 3D echo.

背景:在二尖瓣狭窄(MS)中,左心房(LA)压力升高和心房炎症反应的结合伴随着心房壁间质纤维化的增加,并伴有心房肌束的紊乱、LA功能障碍和随后的LA扩张。我们的目的是评估严重风湿性MS对LA体积和力学的影响。方法:选取单纯重度风湿性MS合并窦性心律的患者40例作为患者组,健康者30例作为对照组。所有患者和对照组均行二维(2D)经胸超声测量左心室(LV)尺寸、功能、左室变形、估计收缩期肺动脉压(EPAP)和左心室整体纵向应变(LV GLS)。通过三维(3D)经胸回声测量左室容积和力学(左室收缩期(储层功能)和左室舒张期(早期=导管,晚期=增压泵=心房收缩)时的左室应变);通过三维经食管回声测量二尖瓣(MV)面积(作为常规经皮前二尖瓣融合切开术,在食管中端长轴视野下采用多平面重建)。结果:经胸二维超声显示,与对照组相比,患者组的所有LA功能均明显降低,包括储层期间LA应变(24±6比43±3,P < 0.001),导管期间LA应变(-11±3比-25±2,P < 0.001),增压泵期间LA应变(-13±4比-18±1,P < 0.001)。患者组EPAP(48±7)明显高于对照组(27±4)。患者组LV GLS明显低于对照组(-16±2%,对照组-23±2%)。患者组所有三维左室容积均显著高于对照组,包括最大左室容积(LAVmax)(76±18比50±5,P < 0.001)、指标左室容积(LAVi)(44.6±10.1比28.7±3.7,P < 0.001)、左室最小容积(LAVmin)(51±15比30±4,P < 0.001)、左室收缩前容积(LAVpre A)(63±15比41±6,P < 0.001)。3D斑点追踪回声显示,患者组LA应变明显降低,包括LA收缩变形(储层功能)(23±6比41±3,P < 0.001)和舒张变形、舒张早期(导管功能)(-10±2比-24±2,P < 0.001)和舒张晚期(增压泵功能)(-13±4比-18±1,P < 0.001)。结论:单纯重度风湿性ms的LA功能均明显降低,LA力学的降低与狭窄的MV区缩小程度直接相关。重度MS时左室GLS明显降低,其降低程度与狭窄MV区和三维回波对LAVi的降低程度直接相关。
{"title":"Left Atrial Remodeling in Patients With Severe Rheumatic Mitral Stenosis and Sinus Rhythm Using Two-Dimensional and Three-Dimensional Speckle Tracking Echocardiography.","authors":"Taher Said Abd Elkareem,&nbsp;Taghreed Abdelrahman Ahmed,&nbsp;Layla Ahmed Mohamed","doi":"10.14740/cr1465","DOIUrl":"https://doi.org/10.14740/cr1465","url":null,"abstract":"<p><strong>Background: </strong>In mitral stenosis (MS), the combination of an increase in left atrium (LA) pressure and atrial inflammatory response is accompanied by increase in interstitial fibrosis of the atrial wall with disorganization of atrial muscle bundles, LA dysfunction and subsequently LA dilatation. We aimed to assess the effect of severe rheumatic MS on LA volumes and mechanics.</p><p><strong>Methods: </strong>We enrolled 40 patients with pure severe rheumatic MS and sinus rhythm as a patient group and 30 healthy subjects as a control group. All patient and control groups underwent two-dimensional (2D) transthoracic echo to measure left ventricle (LV) dimensions, function, LA deformations, estimated systolic pulmonary artery pressure (EPAP), and left ventricle global longitudinal strain (LV GLS). Also LA volumes and mechanics (LA strain during LV systole (reservoir function) and LV diastole (early = conduit, and late = booster pump = atrial contraction)) were measured by three-dimensional (3D) transthoracic echo; mitral valve (MV) area was measured by 3D transesophageal echo (as routine pre-percutaneous MV commissurotomy using multiplanar reconstruction in mid-esophageal apical long-axis view from LA prospective).</p><p><strong>Results: </strong>By 2D transthoracic echo, patient group revealed significantly lower all LA function vs. control group including LA strain during reservoir (24 ± 6 vs. 43 ± 3, P < 0.001), LA strain during conduit (-11 ± 3 vs. -25 ± 2, P < 0.001), and during booster pump (-13 ± 4 vs. -18 ± 1, P < 0.001). EPAP was significantly higher in patient group (48 ± 7 vs. 27 ± 4 in control group). LV GLS was significantly lower in patient group (-16±2% vs. -23±2% in control group). All 3D LA volumes were significantly higher in patient group than control group including maximum LA volume (LAVmax) (76 ± 18 vs. 50 ± 5, P < 0.001), indexed LA volume (LAVi) (44.6 ± 10.1 vs. 28.7 ± 3.7, P < 0.001), LV minimum volume (LAVmin) (51 ± 15 vs. 30 ± 4, P < 0.001), and LA volume pre atrial contraction (LAVpre A) (63 ± 15 vs. 41 ± 6, P < 0.001). Also, there was significantly decreased LA strain using 3D speckle tracking echo in patient group including systolic deformation of LA (reservoir function) (23 ± 6 vs. 41 ± 3, P < 0.001) and diastolic deformation, early diastole (conduit function) (-10 ± 2 vs. -24 ± 2, P < 0.001), and late diastole (booster pump function) (-13 ± 4 vs. -18 ± 1, P < 0.001).</p><p><strong>Conclusions: </strong>All LA function markedly reduced in pure severe rheumatic MS. The reduction of LA mechanics is directly related to the degree of reduction of the stenotic MV area. LV GLS significantly reduced in severe MS and its reduction is directly related to the degree of reduction of the stenotic MV area and the LAVi by 3D echo.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"14 2","pages":"142-148"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/0e/cr-14-142.PMC10116933.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9390008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immobilizing Interstitial Cardiac Fibrosis. 固定化间质性心脏纤维化。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-04-01 DOI: 10.14740/cr1467
Yuriy L Shevchenko, Alexey V Plotnitsky, Daniil S Ulbashev

Background: The alterations in the endomysium and perimysium might cause compaction and gradual mechanical compression of cardiomyocytes resulting in their immobilization. This process finally leads to severe stiffening, so that the newly formed frame around individual cardiomyocytes and their clusters hinders normal diastole, and later systole. This phenomenon is referred to as immobilizing interstitial cardiac fibrosis (IICF). Deciphering the molecular and structural elements of myocardial changes is the key to understanding the pathogenetic foundations of heart failure development.

Methods: The study included 69 patients. Group I (n = 32) included patients with IICF; group II (n = 37) was comparison group. We evaluated the clinical picture, anamnesis of the disease, the results of physical examination, laboratory and instrumental examination of patients and autopsy data.

Results: In the anamnesis, patients with IICF were more likely to have diseases than patients in the control group: arrhythmia and impaired conductivity (88% vs. 19%, odds ratio (OR): 30.0; 95% confidence interval (CI): 7.918 - 113.7, P < 0.001), systemic connective tissue diseases (78% vs. 5%, OR: 62.5; 95% CI: 11.9 - 326.5, P < 0.001), viral infections (including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) (53% vs. 19%, OR: 4.86; 95% CI: 1.66 - 14.25, P = 0.003), type 2 diabetes mellitus (47% vs. 8%, OR: 10.0; 95% CI: 2.54 - 39.34, P < 0.001), radiation therapy for mediastinal lymphoma and other oncological diseases (19% vs. 0%, P = 0.008), focal infections (sinusitis, osteomyelitis, periodontitis, nephritis, cystitis, pyelonephritis, pleurisy, etc.) within 12 months (31% vs. 11%, P = 0.069), chronic kidney disease (25% vs. 8%, P = 0.097), and tuberculosis (9% vs. 0%, P = 0.095). We have identified a statistically significant difference between the groups: the volume of the fibrosis zone (17.5±9.2% vs. 4.9±2.3%, P = 0.001), the expression of type I collagen (5,182 ± 1,301 vs. 2,189 ± 754 in 1 mm2, P = 0.0001), type III collagen (7,562 ± 1,405 vs. 2,320 ± 541 in 1 mm2, P = 0.0001), matrix metalloproteinase (MMP)-2 (12,850 ± 6,200 vs. 9,501 ± 7,145 in 1 mm2, P = 0.005), MMP-9 (15,745 ± 5,695 vs. 6,920 ± 3,125 in 1 mm2, P = 0.0001), connexin-43 (25,689 ± 14,871 vs. 37,523 ± 12,561 in 1 mm2, P = 0.001), fibronectin (3,448 ± 720 vs. 1,544 ± 610 in 1 mm2, P = 0.0001), and transforming growth factor β (TGF-β) (5,121 ± 1,243 vs. 2,531 ± 1,489 in 1 mm2, P = 0.001).

Conclusion: IICF is a separate pathological condition and one of the main causes of chronic heart failure. It is induced by changes in the myocardial connective tissue that prevent normal functioning of the myocardium.

背景:肌内膜和肌周膜的改变可能引起心肌细胞的压实和逐渐的机械压迫,导致它们的固定。这一过程最终导致严重的硬化,因此单个心肌细胞及其簇周围新形成的框架阻碍了正常的舒张和随后的收缩。这种现象被称为固定化间质性心脏纤维化(IICF)。破译心肌变化的分子和结构因素是了解心力衰竭发展的病理基础的关键。方法:纳入69例患者。第一组(n = 32)包括IICF患者;第二组(n = 37)为对照组。我们评估了临床表现,疾病的记忆,体检结果,实验室和仪器检查的病人和尸检数据。结果:在记忆中,IICF患者比对照组患者更容易出现疾病:心律失常和电导率受损(88%对19%,优势比(OR): 30.0;95%可信区间(CI): 7.918 ~ 113.7, P < 0.001),系统性结缔组织疾病(78% vs. 5%, OR: 62.5;95% CI: 11.9 - 326.5, P < 0.001),病毒感染(包括严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)) (53% vs. 19%, OR: 4.86;95% CI: 1.66 - 14.25, P = 0.003), 2型糖尿病(47%对8%,OR: 10.0;95% CI: 2.54 ~ 39.34, P < 0.001),纵隔淋巴瘤等肿瘤疾病(19% vs. 0%, P = 0.008), 12个月内局灶性感染(鼻窦炎、骨髓炎、牙周炎、肾炎、膀胱炎、肾盂肾炎、胸膜炎等)(31% vs. 11%, P = 0.069),慢性肾脏疾病(25% vs. 8%, P = 0.097),结核病(9% vs. 0%, P = 0.095)。我们发现两组之间存在统计学上的显著差异:纤维化区域的体积(17.5±9.2%和4.9±2.3%,P = 0.001), I型胶原蛋白的表达(5182±1301和2189±754年1平方毫米,P = 0.0001), III型胶原蛋白(7562±1405和2320±541年1平方毫米,P = 0.0001),基质金属蛋白酶(MMP) 2(12850±6200和9501±7145年1平方毫米,P = 0.005), MMP-9(15745±5695和6920±3125年1平方毫米,P = 0.0001), connexin-43(25689±14871和37523±12561年1平方毫米,P = 0.001),纤维连接蛋白(3,448±720比1,544±610,1 mm2, P = 0.0001)和转化生长因子β (TGF-β)(5,121±1,243比2,531±1,489,P = 0.001)。结论:IICF是一种独立的病理状态,是慢性心力衰竭的主要原因之一。它是由心肌结缔组织的变化引起的,这种变化阻止了心肌的正常功能。
{"title":"Immobilizing Interstitial Cardiac Fibrosis.","authors":"Yuriy L Shevchenko,&nbsp;Alexey V Plotnitsky,&nbsp;Daniil S Ulbashev","doi":"10.14740/cr1467","DOIUrl":"https://doi.org/10.14740/cr1467","url":null,"abstract":"<p><strong>Background: </strong>The alterations in the endomysium and perimysium might cause compaction and gradual mechanical compression of cardiomyocytes resulting in their immobilization. This process finally leads to severe stiffening, so that the newly formed frame around individual cardiomyocytes and their clusters hinders normal diastole, and later systole. This phenomenon is referred to as immobilizing interstitial cardiac fibrosis (IICF). Deciphering the molecular and structural elements of myocardial changes is the key to understanding the pathogenetic foundations of heart failure development.</p><p><strong>Methods: </strong>The study included 69 patients. Group I (n = 32) included patients with IICF; group II (n = 37) was comparison group. We evaluated the clinical picture, anamnesis of the disease, the results of physical examination, laboratory and instrumental examination of patients and autopsy data.</p><p><strong>Results: </strong>In the anamnesis, patients with IICF were more likely to have diseases than patients in the control group: arrhythmia and impaired conductivity (88% vs. 19%, odds ratio (OR): 30.0; 95% confidence interval (CI): 7.918 - 113.7, P < 0.001), systemic connective tissue diseases (78% vs. 5%, OR: 62.5; 95% CI: 11.9 - 326.5, P < 0.001), viral infections (including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) (53% vs. 19%, OR: 4.86; 95% CI: 1.66 - 14.25, P = 0.003), type 2 diabetes mellitus (47% vs. 8%, OR: 10.0; 95% CI: 2.54 - 39.34, P < 0.001), radiation therapy for mediastinal lymphoma and other oncological diseases (19% vs. 0%, P = 0.008), focal infections (sinusitis, osteomyelitis, periodontitis, nephritis, cystitis, pyelonephritis, pleurisy, etc.) within 12 months (31% vs. 11%, P = 0.069), chronic kidney disease (25% vs. 8%, P = 0.097), and tuberculosis (9% vs. 0%, P = 0.095). We have identified a statistically significant difference between the groups: the volume of the fibrosis zone (17.5±9.2% vs. 4.9±2.3%, P = 0.001), the expression of type I collagen (5,182 ± 1,301 vs. 2,189 ± 754 in 1 mm<sup>2</sup>, P = 0.0001), type III collagen (7,562 ± 1,405 vs. 2,320 ± 541 in 1 mm<sup>2</sup>, P = 0.0001), matrix metalloproteinase (MMP)-2 (12,850 ± 6,200 vs. 9,501 ± 7,145 in 1 mm<sup>2</sup>, P = 0.005), MMP-9 (15,745 ± 5,695 vs. 6,920 ± 3,125 in 1 mm<sup>2</sup>, P = 0.0001), connexin-43 (25,689 ± 14,871 vs. 37,523 ± 12,561 in 1 mm<sup>2</sup>, P = 0.001), fibronectin (3,448 ± 720 vs. 1,544 ± 610 in 1 mm<sup>2</sup>, P = 0.0001), and transforming growth factor β (TGF-β) (5,121 ± 1,243 vs. 2,531 ± 1,489 in 1 mm<sup>2</sup>, P = 0.001).</p><p><strong>Conclusion: </strong>IICF is a separate pathological condition and one of the main causes of chronic heart failure. It is induced by changes in the myocardial connective tissue that prevent normal functioning of the myocardium.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"14 2","pages":"123-132"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/12/cr-14-123.PMC10116936.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9445391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanism of Increased Spinal Cord Blood Flow due to Noradrenaline Administration Using Vascular Resistance: An Experimental Study Using a Canine Model. 血管阻力对去甲肾上腺素给药后脊髓血流量增加的影响机制:犬模型实验研究。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-04-01 DOI: 10.14740/cr1478
Yuya Kise, Yukio Kuniyoshi, Keita Miyaishi, Mizuki Ando, Shotaro Higa, Tatuya Maeda, Moriyasu Nakaema, Hitoshi Inafuku, Kojiro Furukawa

Background: During thoracoabdominal aortic surgery, the spinal cord is placed under ischemic conditions. Elevation of systemic blood pressure is thus recommended as a method of increasing the blood supply from collateral networks. This study examined the mechanisms by which noradrenaline administration increases spinal cord blood flow (SCBF) by elevating systemic blood pressure.

Methods: In beagles (n = 7), the thoracoabdominal aorta and L2-L7 spinal cord segmental arteries (SAs) were exposed and a distal perfusion bypass was created to simulate clinical practice. SCBF was measured by laser flowmetry at the L5 dura mater and spinal cord perfusion pressure (SCPP) was measured inside the clamped aorta. The six pairs of SAs from L2 to L7 were clamped, and mean systemic blood pressure (mSBP), SCBF, and SCPP were measured before and after clamping and after starting continuous infusion of noradrenaline at 0.5 µg/kg/min. Rates of change in systemic vascular resistance (SVR) and spinal cord vascular resistance (SCVR) were calculated from the measured values.

Results: With no SA clamping (control), the rate of increase in SCVR was 0.74 times the rate of increase in SVR (y = 0.2 + 0.74x, r = 0.889, r2 = 0.789; P < 0.01). When all six pairs of SAs were clamped, a weak correlation was evident between rate of change in SCVR and rate of change in SVR, and the rate of increase in SCVR was lower than the rate of increase in SVR (y = 0.39 + 0.07x, r = 0.209, r2 = 0.039; P < 0.01). When all six pairs of SAs were clamped in the absence of distal perfusion, a weak correlation was also evident between rate of change in SCVR and rate of change in SVR, and the rate of increase in SCVR was lower than the rate of increase in SVR (y = 0.19 + 0.08x, r = 0.379, r2 = 0.144; P < 0.01).

Conclusions: The rate of increase in SCVR induced by noradrenaline administration was lower than the rate of increase in SVR in the control group with no spinal cord SA clamping and in both experimental groups with clamped SAs (with and without distal perfusion), creating an environment conducive to spinal cord flow distribution.

背景:在胸腹主动脉手术中,脊髓处于缺血状态。因此,建议将体表血压升高作为增加侧枝网络供血的一种方法。本研究探讨了去甲肾上腺素通过升高全身血压来增加脊髓血流量(SCBF)的机制。方法:取比格犬(n = 7),暴露胸腹主动脉和L2-L7脊髓节段动脉(SAs),建立远端灌注旁路模拟临床。采用激光血流仪测量L5硬脑膜SCBF,测定夹紧主动脉内脊髓灌注压(SCPP)。夹持L2 ~ L7的6对SAs,分别在夹持前后和开始以0.5µg/kg/min持续输注去甲肾上腺素后测量平均体血压(mSBP)、SCBF、SCPP。根据测量值计算全身血管阻力(SVR)和脊髓血管阻力(SCVR)的变化率。结果:未夹持SA组(对照组)SCVR的增加率是SVR增加率的0.74倍(y = 0.2 + 0.74x, r = 0.889, r2 = 0.789;P < 0.01)。当所有6对sa均夹持时,SCVR变化率与SVR变化率之间呈明显的弱相关,SCVR的增加速率低于SVR的增加速率(y = 0.39 + 0.07x, r = 0.209, r2 = 0.039;P < 0.01)。在没有远端灌注的情况下夹持所有6对sa时,SCVR变化率与SVR变化率之间也存在明显的弱相关,SCVR的增加速率低于SVR的增加速率(y = 0.19 + 0.08x, r = 0.379, r2 = 0.144;P < 0.01)。结论:未夹持脊髓SA的对照组和夹持脊髓SA(有远端灌注和无远端灌注)的实验组,去甲肾上腺素诱导SCVR的增加率低于SVR的增加率,创造了有利于脊髓血流分布的环境。
{"title":"Mechanism of Increased Spinal Cord Blood Flow due to Noradrenaline Administration Using Vascular Resistance: An Experimental Study Using a Canine Model.","authors":"Yuya Kise,&nbsp;Yukio Kuniyoshi,&nbsp;Keita Miyaishi,&nbsp;Mizuki Ando,&nbsp;Shotaro Higa,&nbsp;Tatuya Maeda,&nbsp;Moriyasu Nakaema,&nbsp;Hitoshi Inafuku,&nbsp;Kojiro Furukawa","doi":"10.14740/cr1478","DOIUrl":"https://doi.org/10.14740/cr1478","url":null,"abstract":"<p><strong>Background: </strong>During thoracoabdominal aortic surgery, the spinal cord is placed under ischemic conditions. Elevation of systemic blood pressure is thus recommended as a method of increasing the blood supply from collateral networks. This study examined the mechanisms by which noradrenaline administration increases spinal cord blood flow (SCBF) by elevating systemic blood pressure.</p><p><strong>Methods: </strong>In beagles (<i>n</i> = 7), the thoracoabdominal aorta and L2-L7 spinal cord segmental arteries (SAs) were exposed and a distal perfusion bypass was created to simulate clinical practice. SCBF was measured by laser flowmetry at the L5 dura mater and spinal cord perfusion pressure (SCPP) was measured inside the clamped aorta. The six pairs of SAs from L2 to L7 were clamped, and mean systemic blood pressure (mSBP), SCBF, and SCPP were measured before and after clamping and after starting continuous infusion of noradrenaline at 0.5 µg/kg/min. Rates of change in systemic vascular resistance (SVR) and spinal cord vascular resistance (SCVR) were calculated from the measured values.</p><p><strong>Results: </strong>With no SA clamping (control), the rate of increase in SCVR was 0.74 times the rate of increase in SVR (y = 0.2 + 0.74x, r = 0.889, r<sup>2</sup> = 0.789; P < 0.01). When all six pairs of SAs were clamped, a weak correlation was evident between rate of change in SCVR and rate of change in SVR, and the rate of increase in SCVR was lower than the rate of increase in SVR (y = 0.39 + 0.07x, r = 0.209, r<sup>2</sup> = 0.039; P < 0.01). When all six pairs of SAs were clamped in the absence of distal perfusion, a weak correlation was also evident between rate of change in SCVR and rate of change in SVR, and the rate of increase in SCVR was lower than the rate of increase in SVR (y = 0.19 + 0.08x, r = 0.379, r<sup>2</sup> = 0.144; P < 0.01).</p><p><strong>Conclusions: </strong>The rate of increase in SCVR induced by noradrenaline administration was lower than the rate of increase in SVR in the control group with no spinal cord SA clamping and in both experimental groups with clamped SAs (with and without distal perfusion), creating an environment conducive to spinal cord flow distribution.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"14 2","pages":"115-122"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/1a/cr-14-115.PMC10116934.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9445396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Major Adverse Cardiovascular Events and the Gensini Score or Coronary Artery Calcification Score in Hypertensive Patients Who Have Undergone Coronary Computed Tomography Angiography. 接受冠状动脉ct血管造影的高血压患者的主要不良心血管事件与Gensini评分或冠状动脉钙化评分之间的关系
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-04-01 DOI: 10.14740/cr1453
Yuhei Shiga, Kohei Tashiro, Erica Miura, Sara Higashi, Yuto Kawahira, Takashi Kuwano, Makoto Sugihara, Shin-Ichiro Miura

Background: From the Fukuoka University Coronary Computed Tomography Angiography (FU-CCTA) registry, we present major adverse cardiovascular events (MACEs) in hypertensive patients who have undergone CCTA, and the association between MACEs and the Gensini score of coronary arteries or the coronary artery calcification (CAC) score.

Methods: Of the patients who underwent CCTA for coronary artery disease (CAD) screening at Fukuoka University Hospital, 318 hypertensive patients who had at least one cardiovascular risk factor or suspected CAD were enrolled. The patients were divided into two groups: MACEs and non-MACEs groups. The severity of atherosclerosis of coronary arteries was assessed by the Gensini score. The CAC score was also defined by computed tomography (CT) images at the time of CCTA. A primary endpoint was MACEs (all-cause death, ischemic stroke, acute myocardial infarction, coronary revascularization). The patients were followed for up to 5 years.

Results: The patients were 68 ± 10 years, and 50% were males. The percentages of smoking, dyslipidemia, diabetes, and chronic kidney disease were 39%, 70%, 26% and 37%, respectively. The %males, %smoking, CAC score and Gensini score in the MACEs group were significantly higher than those in the non-MACEs group. On the other hand, the differences in age, dyslipidemia, diabetes, or chronic kidney disease between the groups were not seen. A multivariate analysis was performed regarding the presence or absence of MACE by logistic regression analysis of the CAC score or Gensini score in addition to conventional risk factors as independent variables. A Cox regression analysis revealed significant relationships for both the CAC score (P = 0.043) and the Gensini score (P = 0.008).

Conclusions: The CAC score and the Gensini score could predict MACEs in hypertensive patients who have undergone CCTA.

背景:来自福冈大学冠状动脉计算机断层血管造影(FU-CCTA)登记,我们报告了接受CCTA的高血压患者的主要不良心血管事件(mace),以及mace与冠状动脉Gensini评分或冠状动脉钙化(CAC)评分之间的关系。方法:在福冈大学医院接受冠心病(CAD)筛查的患者中,纳入318例至少有一种心血管危险因素或疑似冠心病的高血压患者。患者分为两组:恶性肿瘤组和非恶性肿瘤组。冠状动脉粥样硬化的严重程度采用Gensini评分。CCTA时的计算机断层扫描(CT)图像也定义了CAC评分。主要终点是mace(全因死亡、缺血性卒中、急性心肌梗死、冠状动脉血运重建术)。对这些患者进行了长达5年的随访。结果:患者年龄68±10岁,男性占50%。吸烟、血脂异常、糖尿病和慢性肾病的比例分别为39%、70%、26%和37%。mace组男性百分比、吸烟百分比、CAC评分、Gensini评分均显著高于非mace组。另一方面,两组之间在年龄、血脂异常、糖尿病或慢性肾脏疾病方面没有差异。采用logistic回归分析CAC评分或Gensini评分,并将常规危险因素作为自变量,对MACE的存在与否进行多变量分析。Cox回归分析显示CAC评分(P = 0.043)与Gensini评分(P = 0.008)之间存在显著相关。结论:CAC评分和Gensini评分可以预测行CCTA的高血压患者的mace。
{"title":"Association Between Major Adverse Cardiovascular Events and the Gensini Score or Coronary Artery Calcification Score in Hypertensive Patients Who Have Undergone Coronary Computed Tomography Angiography.","authors":"Yuhei Shiga,&nbsp;Kohei Tashiro,&nbsp;Erica Miura,&nbsp;Sara Higashi,&nbsp;Yuto Kawahira,&nbsp;Takashi Kuwano,&nbsp;Makoto Sugihara,&nbsp;Shin-Ichiro Miura","doi":"10.14740/cr1453","DOIUrl":"https://doi.org/10.14740/cr1453","url":null,"abstract":"<p><strong>Background: </strong>From the Fukuoka University Coronary Computed Tomography Angiography (FU-CCTA) registry, we present major adverse cardiovascular events (MACEs) in hypertensive patients who have undergone CCTA, and the association between MACEs and the Gensini score of coronary arteries or the coronary artery calcification (CAC) score.</p><p><strong>Methods: </strong>Of the patients who underwent CCTA for coronary artery disease (CAD) screening at Fukuoka University Hospital, 318 hypertensive patients who had at least one cardiovascular risk factor or suspected CAD were enrolled. The patients were divided into two groups: MACEs and non-MACEs groups. The severity of atherosclerosis of coronary arteries was assessed by the Gensini score. The CAC score was also defined by computed tomography (CT) images at the time of CCTA. A primary endpoint was MACEs (all-cause death, ischemic stroke, acute myocardial infarction, coronary revascularization). The patients were followed for up to 5 years.</p><p><strong>Results: </strong>The patients were 68 ± 10 years, and 50% were males. The percentages of smoking, dyslipidemia, diabetes, and chronic kidney disease were 39%, 70%, 26% and 37%, respectively. The %males, %smoking, CAC score and Gensini score in the MACEs group were significantly higher than those in the non-MACEs group. On the other hand, the differences in age, dyslipidemia, diabetes, or chronic kidney disease between the groups were not seen. A multivariate analysis was performed regarding the presence or absence of MACE by logistic regression analysis of the CAC score or Gensini score in addition to conventional risk factors as independent variables. A Cox regression analysis revealed significant relationships for both the CAC score (P = 0.043) and the Gensini score (P = 0.008).</p><p><strong>Conclusions: </strong>The CAC score and the Gensini score could predict MACEs in hypertensive patients who have undergone CCTA.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"14 2","pages":"91-96"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/29/23/cr-14-091.PMC10116937.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9445394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Nutritional Status in Patients Undergoing Phase II Cardiac Rehabilitation by Mini Nutritional Assessment. 通过Mini营养评估进行II期心脏康复患者的营养状况。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-04-01 DOI: 10.14740/cr1479
Yosuke Nozawa, Miho Nishitani-Yokoyama, Kazunori Shimada, Hiroki Kasuya, Mitsuhiro Kunimoto, Kei Fujiwara, Mayumi Doi, Yusei Sato, Junya Nishimura, Jianying Xu, Abidan Abulimiti, Minoru Tabata, Tohru Minamino

Background: Malnutrition impairs quality of life and prognosis of patients with cardiovascular disease. The Mini Nutritional Assessment (MNA) is a screening tool developed for the nutritional assessment of older adults. However, usefulness of MNA for patients undergoing cardiac rehabilitation (CR) has not been fully investigated.

Methods: From March 2017 to September 2019, the MNA-short form (MNA-SF) and the MNA total score in patients undergoing phase II CR at the Juntendo University Hospital were evaluated.

Results: A total of 336 patients (mean age 70.1 ± 11.4 years; males: 209) were analyzed. In the MNA-SF, 157 patients (47%) were found to be malnourished or at risk of malnutrition. In MNA total score, 168 patients (50%) were found to be malnourished or at risk of malnutrition. The MNA-SF < 12 group had significantly lower body mass index (BMI), hemoglobin level, low MNA scores for protein/water intake, self-evaluation of nutrition and health, and upper arm and calf circumferences compared to the MNA-SF ≥ 12 group. Assuming BMI < 18.5 as malnutrition, the sensitivity and specificity for malnutrition were 100% and 58.9% for MNA-SF, and 96.9% and 54.9% for MNA total score, respectively.

Conclusions: MNA is useful in screening for malnutrition in patients undergoing CR. Approximately 50% of them were determined to be malnourished or at risk of malnutrition, suggesting the need for detailed evaluation regarding their food intake and dietary intervention.

背景:营养不良会影响心血管疾病患者的生活质量和预后。迷你营养评估(MNA)是一种用于老年人营养评估的筛选工具。然而,MNA对心脏康复(CR)患者的有用性尚未得到充分研究。方法:对2017年3月至2019年9月在俊天大学医院接受ⅱ期CR的患者进行MNA短表(MNA- sf)和MNA总分评估。结果:共336例患者(平均年龄70.1±11.4岁;男性209例)。在MNA-SF中,157名患者(47%)被发现营养不良或有营养不良风险。在MNA总分中,168例患者(50%)被发现营养不良或有营养不良风险。与MNA- sf≥12组相比,MNA- sf < 12组的身体质量指数(BMI)、血红蛋白水平、蛋白质/水摄入量、营养和健康自我评估以及上臂和小腿围的MNA评分均较低。假设BMI < 18.5为营养不良,MNA- sf对营养不良的敏感性为100%,特异性为58.9%,MNA总分对营养不良的敏感性为96.9%,特异性为54.9%。结论:MNA在筛查CR患者的营养不良方面是有用的。大约50%的患者被确定为营养不良或有营养不良的风险,这表明需要对他们的食物摄入和饮食干预进行详细评估。
{"title":"Nutritional Status in Patients Undergoing Phase II Cardiac Rehabilitation by Mini Nutritional Assessment.","authors":"Yosuke Nozawa,&nbsp;Miho Nishitani-Yokoyama,&nbsp;Kazunori Shimada,&nbsp;Hiroki Kasuya,&nbsp;Mitsuhiro Kunimoto,&nbsp;Kei Fujiwara,&nbsp;Mayumi Doi,&nbsp;Yusei Sato,&nbsp;Junya Nishimura,&nbsp;Jianying Xu,&nbsp;Abidan Abulimiti,&nbsp;Minoru Tabata,&nbsp;Tohru Minamino","doi":"10.14740/cr1479","DOIUrl":"https://doi.org/10.14740/cr1479","url":null,"abstract":"<p><strong>Background: </strong>Malnutrition impairs quality of life and prognosis of patients with cardiovascular disease. The Mini Nutritional Assessment (MNA) is a screening tool developed for the nutritional assessment of older adults. However, usefulness of MNA for patients undergoing cardiac rehabilitation (CR) has not been fully investigated.</p><p><strong>Methods: </strong>From March 2017 to September 2019, the MNA-short form (MNA-SF) and the MNA total score in patients undergoing phase II CR at the Juntendo University Hospital were evaluated.</p><p><strong>Results: </strong>A total of 336 patients (mean age 70.1 ± 11.4 years; males: 209) were analyzed. In the MNA-SF, 157 patients (47%) were found to be malnourished or at risk of malnutrition. In MNA total score, 168 patients (50%) were found to be malnourished or at risk of malnutrition. The MNA-SF < 12 group had significantly lower body mass index (BMI), hemoglobin level, low MNA scores for protein/water intake, self-evaluation of nutrition and health, and upper arm and calf circumferences compared to the MNA-SF ≥ 12 group. Assuming BMI < 18.5 as malnutrition, the sensitivity and specificity for malnutrition were 100% and 58.9% for MNA-SF, and 96.9% and 54.9% for MNA total score, respectively.</p><p><strong>Conclusions: </strong>MNA is useful in screening for malnutrition in patients undergoing CR. Approximately 50% of them were determined to be malnourished or at risk of malnutrition, suggesting the need for detailed evaluation regarding their food intake and dietary intervention.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"14 2","pages":"133-141"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4e/2a/cr-14-133.PMC10116935.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9742654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Left Axillary Access for Transcatheter Aortic Valve Implantation in a Patient With Two Dependent Internal Mammary Artery Grafts and a Permanent Left-Sided Implanted Pacemaker. 左腋通道经导管主动脉瓣置入术治疗双侧乳腺内动脉和左侧永久性起搏器植入术患者。
IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2023-04-01 DOI: 10.14740/cr1495
Christos Papageorgiou, Konstantinos Tampakis, Anastasios Chronopoulos, Vaios Tzifos

Transfemoral access has been established as the gold standard approach for the majority of patients undergoing transcatheter aortic valve implantation (TAVI). However, in cases with anatomical difficulties or severely diffused peripheral arterial disease, alternative vascular access may be considered such as the transaxillary approach. We present the case of a 92-year-old gentleman with exertional dyspnea due to severe symptomatic aortic stenosis and a history of peripheral femoro-femoral bypass surgery, coronary arterial bypass surgery and a permanent dual-chamber left-side implanted pacemaker. Due to the high surgical risk and the severe anatomical difficulties, the method of TAVI using the left axillary approach was opted. A 14-F vascular sheath was inserted with surgical cutdown and with fluoroscopic guidance while small injections of contrast confirmed the non-occlusive position and the patency of the left internal mammary artery (LIMA) graft. A stiff guidewire was used to cross the heavily calcified aortic valve and subsequently was placed into the left ventricle. Balloon aortic valvuloplasty was performed followed by a successful TAVI with no significant aortic regurgitation or paravalvular leak. The patient recuperated uneventfully and was discharged after 72 h. Axillary access for TAVI is a feasible option for high-risk patients with extended peripheral arteriopathy. To our knowledge this is the first case report describing the implantation of a newer type of intra-annular self-expanding valve platform in a nonagenarian patient with severe comorbidities and such a remarkable history of multiple previous interventions in the selected access site. Meticulous upfront strategy planning and efficient collaboration between specialties is of outmost importance in hybrid procedures for favorable clinical outcomes, especially in cases with challenging anatomies.

经股骨入路已被确立为大多数经导管主动脉瓣植入术(TAVI)患者的金标准入路。然而,在解剖困难或严重弥漫性外周动脉疾病的情况下,可考虑其他血管通路,如经腋窝入路。我们报告一位92岁的男士,由于严重的症状性主动脉瓣狭窄,有外周股-股搭桥手术、冠状动脉搭桥手术和永久性双腔左侧植入起搏器的病史。由于手术风险高,解剖难度大,我们选择了经左腋窝入路行TAVI。在手术切开和透视引导下插入14-F血管鞘,同时小剂量注射造影剂确认左乳内动脉(LIMA)移植物的非闭塞位置和通畅。使用硬导丝穿过严重钙化的主动脉瓣,随后将其置入左心室。球囊主动脉瓣成形术后进行了成功的TAVI,没有明显的主动脉反流或瓣旁泄漏。患者恢复平稳,72小时后出院。对于扩展外周动脉病变的高危患者,腋窝入路TAVI是一种可行的选择。据我们所知,这是第一例描述在一名患有严重合并症的90多岁患者中植入新型环内自膨胀瓣膜平台的病例报告,并且在选定的通路部位有多次干预的显著历史。在混合手术中,细致的前期策略规划和专业之间的有效合作对于获得良好的临床结果至关重要,特别是在具有挑战性解剖结构的病例中。
{"title":"Left Axillary Access for Transcatheter Aortic Valve Implantation in a Patient With Two Dependent Internal Mammary Artery Grafts and a Permanent Left-Sided Implanted Pacemaker.","authors":"Christos Papageorgiou,&nbsp;Konstantinos Tampakis,&nbsp;Anastasios Chronopoulos,&nbsp;Vaios Tzifos","doi":"10.14740/cr1495","DOIUrl":"https://doi.org/10.14740/cr1495","url":null,"abstract":"<p><p>Transfemoral access has been established as the gold standard approach for the majority of patients undergoing transcatheter aortic valve implantation (TAVI). However, in cases with anatomical difficulties or severely diffused peripheral arterial disease, alternative vascular access may be considered such as the transaxillary approach. We present the case of a 92-year-old gentleman with exertional dyspnea due to severe symptomatic aortic stenosis and a history of peripheral femoro-femoral bypass surgery, coronary arterial bypass surgery and a permanent dual-chamber left-side implanted pacemaker. Due to the high surgical risk and the severe anatomical difficulties, the method of TAVI using the left axillary approach was opted. A 14-F vascular sheath was inserted with surgical cutdown and with fluoroscopic guidance while small injections of contrast confirmed the non-occlusive position and the patency of the left internal mammary artery (LIMA) graft. A stiff guidewire was used to cross the heavily calcified aortic valve and subsequently was placed into the left ventricle. Balloon aortic valvuloplasty was performed followed by a successful TAVI with no significant aortic regurgitation or paravalvular leak. The patient recuperated uneventfully and was discharged after 72 h. Axillary access for TAVI is a feasible option for high-risk patients with extended peripheral arteriopathy. To our knowledge this is the first case report describing the implantation of a newer type of intra-annular self-expanding valve platform in a nonagenarian patient with severe comorbidities and such a remarkable history of multiple previous interventions in the selected access site. Meticulous upfront strategy planning and efficient collaboration between specialties is of outmost importance in hybrid procedures for favorable clinical outcomes, especially in cases with challenging anatomies.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"14 2","pages":"153-157"},"PeriodicalIF":1.9,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/51/89/cr-14-153.PMC10116938.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9445392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiology Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1